Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial

Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
doi: https://doi.org/10.1101/2021.01.05.21249310

Article usage

Article usage: January 2021 to November 2023

AbstractFullPdf
Jan 20211753811302364
Feb 20215398672828
Mar 202154942921279
Apr 202141432161154
May 202123622541214
Jun 20212242159713
Jul 20213659119542
Aug 20213394119620
Sep 2021358853780
Oct 20212852354384
Nov 20211738536210
Dec 2021174053269
Jan 2022113571320
Feb 202256946121
Mar 202243330148
Apr 20223091392
May 20222561977
Jun 20222332386
Jul 20222411871
Aug 2022224878
Sep 2022245880
Oct 2022262463
Nov 2022548355
Dec 2022213847
Jan 20231721246
Feb 20231281442
Mar 2023120630
Apr 202384538
May 202388436
Jun 202393621
Jul 202371219
Aug 20231544430
Sep 20231091156
Oct 202363636
Nov 2023791129
Back to top
Posted January 09, 2021.
Download PDF
Data/Code
Email
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area